KP-2025

RMP114-mIgG1-D265A

Home » Antibody » RMP114-mIgG1-D265A

Background

The RMP1-14 monoclonal antibody reacts with mouse PD-1 (programmed death-1) also known as CD279. However, RMP1-14 mAb is produced in rats and is therefore immunogenic in mice, and can promote antibody-dependent cytotoxicity. To overcome this issue, RMP114-mIgG1 was generated by recombinant DNA technology. It contains the constant region of mouse IgG1 with a D265A point mutation (replacement of aspartic acid by alanine at position 265) resulting in the complete loss of cytolytic effector function.

Specifications

Catalog Number:
KP-2025
Cell Line Name:
RMP114-mIgG1-D265A
Price:
0
Host Cell Line:
EXPI-CHO
Target:
Mouse-PD1
Species Reactivity:
Mouse
Application:
ELISA | FACS | FACS Blocking | Animal experiment
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2¦Ìm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20¡ãC to -80¡ãC; Stored at 2-8¡ãC for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA | FACS | FACS Blocking | Animal experiment

References

1. Ribas A. & Wolchock J.D., 2018. Cancer immunotherapy using checkpoint blockade. Science. 359:1350-55. 2. Yamazaki T. et al.,2005. Blockade of B7-H1 on macrophages suppresses CD4+ T cell proliferation by augmenting IFN-gamma-induced nitric oxide production. J Immunol. 175(3):1586-92. 3. Br¨¹ggemann M. et al., 1989. The immunogenicity of chimeric antibodies. J. Exp. Med. 170:2153-2157. 4. Mall C. et al., 2016. Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer. Oncoimmunology. 5(2):e1075114
Please enable JavaScript in your browser to complete this form.